Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors

Dominique S. Meyer1, Heike Brinkhaus1, Urs Müller1, Matthias Müller2, Robert D. Cardiff3, and Mohamed Bentires-Alj1

Abstract

The phosphoinositide 3-kinase (PI3K) signaling cascade, a key mediator of cellular survival, growth, and metabolism, is frequently altered in human cancer. Activating mutations in PIK3CA, which encodes the α-catalytic subunit of PI3K, occur in approximately 30% of breast cancers. These mutations result in constitutive activity of the enzyme and are oncogenic, but it is not known whether they are sufficient to induce mammary carcinomas in mice. In the present study, we show that the expression of mutant PIK3CA H1047R in the luminal mammary epithelium evokes heterogeneous tumors that express luminal and basal markers and are positive for the estrogen receptor. Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R.

Introduction

Breast cancer is a complex and heterogeneous disease, probably due to the diversity of transforming events and mammary cells in which they occur, as well as to the cross-talk between the transformed epithelium and the surrounding stroma during breast tumorigenesis (1). Definition of the molecular and cellular alterations causing breast tumor heterogeneity should increase our understanding of breast cancer pathogenesis and support the design of optimal therapeutic strategies.

The phosphoinositide 3-kinase (PI3K) pathway, a central regulator of diverse normal cellular functions, is often subverted during neoplastic transformation (2). Mechanisms of activation of the PI3K pathway in cancer include (i) the mutation and/or amplification of PIK3CA, the gene encoding the α-catalytic subunit of the kinase (p110α); (ii) the loss of expression of the PTEN phosphatase that reverses PI3K action; (iii) the activation downstream of oncogenic receptor tyrosine kinases; and (iv) the mutation/amplification of Akt. A hyperactive PI3K pathway results in cancer cells that have a competitive advantage by decreasing cell death and increasing cell proliferation, migration, invasion, metabolism, angiogenesis, and resistance to chemotherapy.

PIK3CA is mutated in approximately 30% of human breast cancers with nearly 80% of the mutations occurring at 3 hotspots: E542K (~4% of human breast cancers) and E545K (~6%) within the helical domain, and H1047R (~15%) within the kinase domain of p110α (3–5). These mutations result in a constitutively active enzyme that transforms cells in vitro and increases tumorigenicity in xenograft models (6–9). The increase in lipid kinase activity of the mutated p110α makes it a "druggable" target, and several inhibitors have entered phase I/II clinical trials (10, 11). Mutations in PIK3CA are more frequent in estrogen receptor (ER)-positive and HER2-positive tumors than in basal-like breast cancers (12). Reported correlations between PIK3CA mutations and prognosis are contradictory; studies comprising large numbers of patients have shown a paradoxical correlation of PIK3CA mutations with good prognosis (12–15).

PIK3CA mutations have been reported in breast ductal carcinoma in situ (DCIS; ref. 16), and the mutation frequencies in pure DCIS, DCIS adjacent to invasive ductal carcinoma (IDC), and IDC (17) are similar. Thus, mutations of PIK3CA appear to occur early in breast tumorigenesis. To test the hypothesis that PIK3CA mutation initiates mammary tumors, we generated a mouse model conditionally expressing PIK3CA H1047R. In this study, we show that the expression of this mutation in the mammary gland induces carcinomas with different phenotypes composed of cells expressing luminal markers or basal markers or both, and a significant number expressing ER.

Materials and Methods

Transgenic mice

We constructed a vector with a transcriptional STOP sequence flanked by loxP sites upstream of the 5'-terminally
hemagglutinin (HA)-tagged human PIK3CA cDNA (Addgene) and an IRES2-EGFP reporter element (pIRES2-EGFP Vector; Clontech). The resultingloxPSTOP-loxP-5’/HA-PIK3CA-IRES2-EGFP fragment was cloned into a recombinase-mediated cassette exchange (RMCE) plasmid. The vector was introduced into the modified Rosa26 locus of Balb/c mouse embryonic stem (ES) cells by RMCE, and the ES cells were used for blastocyst injection (18). Chimeric mice were mated with Balb/c mice, and transgenic mice were identified by genotyping using the primers 5’-TGCGCATCCTCTAGGATT-3’ and 5’-GAATAACATGGGCTACTTCAT-3’.

Reverse transcriptase-PCR

RNA was isolated from mouse tissue using TRIzol (Invitrogen). TaqMan polymerase and appropriate buffers were purchased from NEB. Human PIK3CA was detected using the primers 5’-CAGATCCCAGTGTGGTGGTACG-3’ and 5’-CATCAAGAAGGTGGTCTCATCC-3’. The PCR product was cloned into a recombination-mediated cassette exchange (RMCE) plasmid. The vector was introduced into the modified Rosa26 locus of Balb/c mouse embryonic stem (ES) cells by RMCE, and the ES cells were used for blastocyst injection (18). Chimeric mice were mated with Balb/c mice, and transgenic mice were identified by genotyping using the primers 5’-TGCGCATCCTCTAGGATT-3’ and 5’-GAATAACATGGGCTACTTCAT-3’.

Results and Discussion

Expression of PIK3CA H1047R in luminal mammary epithelial cells induces carcinomas

To test whether PIK3CA H1047R evokes mammary carcinoma, we generated transgenic mice that conditionally expressed this mutation in mammary epithelium. The correct integration of the construct in ES cells conditionally expressing PIK3CA H1047R (Fig. 1A) was tested by Southern blotting and PCR (Fig. 1B, left; data not shown). The ES cells were used to generate the H1047R line, and the mutation was confirmed by DNA sequencing (Fig. 1B, right). Next, H1047R animals were crossed to WAPiCre mice in which expression of recombinase Cre was driven by the whey acidic protein (WAP) promoter, which is active in alveolar progenitor cells and differentiated secretory luminal cells (20–23). Furthermore, we crossed H1047R animals to mice expressing Cre under the control of the mouse mammary tumor virus (MMTV) long terminal repeat, which results in expression within luminal mammary epithelial cells (19).

Female bitransgenic WAPiCre H1047R mice and littermate controls (WAPiCre) were generated. Mammary glands from WAPiCre mice had GFP-positive areas indicating expression of the oncogene (Fig. 1C, left). This is consistent with previous studies that reported activity of the WAP promoter in a fraction of mammary epithelial cells in virgin mice (21, 23). Examination of whole mounts and hematoxylin and eosin (H&E)-stained sections revealed an average of 5.7 ± 2.2 neoplastic lesions in glands from 21- to 24-week-old virgin WAPiCre mice but not from WAPiCre mice up to 18 weeks of age or age-matched littermate controls (Fig. 1C, right).

The WAPiCre H1047R and control mice were impregnated to achieve maximal Cre-mediated recombination, and the pups were removed the day after delivery. Although parous WAPiCre mice did not form tumors, WAPiCre H1047R mice developed mammary tumors, on average, after 140.3 ± 6.9 days after delivery of the pups, corresponding to an age of 140.3 ± 6.9 days (Fig. 2A). Bitransgenic MMTV-Cre H1047R mice and littermate controls (MMTV-Cre) were generated and left as virgins. Surprisingly, approximately 75% of the MMTV-Cre H1047R animals died before the age of 4 months. Although we did not identify the cause of death, we consider that leakiness of the MMTV promoter causing deleterious H1047R expression in tissues other than the mammary gland was a likely cause (D.S. Meyer and M. Bentires-Alj, unpublished observations). However, approximately 25% of the MMTV-Cre H1047R mice were viable and formed mammary carcinomas, on average, after 214 ± 22.6 days, whereas no tumors were detected in MMTV-Cre control mice (Fig. 2B). Because the average age of tumor onset between parous WAPiCre H1047R and virgin MMTV-Cre H1047R mice differs by approximately 75 days (140.3 vs. 214 days), we sought to investigate whether pregnancy accelerates PIK3CA H1047R-driven tumorigenesis. To address this question, we compared tumor onset in nulliparous and parous WAPiCre H1047R mice and found tumor onset to occur significantly earlier in parous mice than in nulliparous mice (Fig. 2C). These data show that pregnancy accelerates tumor onset in WAPiCre H1047R mice.

We then comparatively assessed the mechanisms underlying the accelerated tumor onset seen in parous against those in nulliparous WAPiCre H1047R mice. Fluorescence imaging and Western blot analysis showed enhanced GFP expression in glands from parous mice, indicating an increase in the number of cells that underwent Cre-mediated recombination and thus expressed H1047R (Supplementary Fig. S1). In addition, whole mounts of the involuting glands revealed a dramatic delay in involution in mice expressing PIK3CA H1047R compared with control animals (Supplementary Fig. S2A), which is in line with...
previous reports of a delayed involution when the PI3K pathway is hyperactivated (24, 25). Immunostaining for cleaved caspase-3 revealed a reduction in the number of apoptotic cells in involuting glands from WAPiCre H1047R mice compared with control mice, suggesting that reduced cell death is the cause of the delayed involution (Supplementary Fig. S2B and C). Our results suggest, therefore, that the acceleration of tumor onset is most likely due to an increase in the number of cells expressing PIK3CA H1047R in parous glands and to impaired cell death in involuting glands with the H1047R mutation. Indeed, pregnancy-induced proliferation could facilitate the acquisition of further genomic alterations and, therefore, accelerate tumorigenesis.

Analysis of RNA and proteins from WAPiCre H1047R and MMTV-Cre H1047R-induced tumors confirmed that mutant PIK3CA was expressed in the transgenic mice (Fig. 3A and B). In addition, tumors from both WAPiCre H1047R and MMTV-Cre H1047R mice showed 3-fold and 8-fold higher phospho-Akt (p-Akt) levels than mammary tumors from the MMTV-NeuNT model, respectively. In contrast, activation of the Erk1/2 pathway in PIK3CA H1047R tumors tended to be weaker than in tumors from MMTV-NeuNT mice (Fig. 3C).

Our results show that luminal expression of PIK3CA H1047R induces mammary tumor formation. This is consistent with the observation that conditional expression of mutant PIK3CA H1047R in type II lung alveolar epithelial cells causes lung adenocarcinomas in transgenic mice (26) and suggests that this mutation plays a causal role in epithelial cancers.

WAPiCre H1047R and MMTV-Cre H1047R–evoked mammary tumors are heterogeneous

To gain insight into significant pathophysiologic features, 22 WAPiCre H1047R and 21 MMTV-Cre H1047R-induced mammary tumors were characterized histologically. MMTV-Cre H1047R-caused tumors showed multiple adenomyoepitheliomas, with clusters of well-delineated polyoid tumors composed of a mixture of glandular epithelium and interstitial fusiform cells having abundant polar cytoplasm (Fig. 4A, top left). Similar tumors have been reported in MMTV-Cre/Pten<sup>−/−</sup>/ErbB2<sup>−/−</sup> mice, suggesting that an activated PI3K pathway mediates this histotype (27).
In contrast, the WAPiCre H1047R mice formed a more diverse spectrum of tumors with 5 distinct histotypes. The most prevalent tumor phenotypes found are adenosquamous carcinomas (54.6%) and adenomyoepitheliomas (22.7%). Furthermore, adenocarcinomas with squamous metaplasia (13.6%) and adenocarcinomas (9.1%) were observed, albeit at lower frequencies (Fig. 4A and B). All the glands surrounding the tumors displayed diffuse adenocarcinomatosis with invasive periductal cords of neoplastic epithelial cells in dense connective tissue (Fig. 4A, top right).

To further characterize H1047R-induced carcinomas, tumors were stained for luminal cytokeratin 18 (K18), basal/myoepithelial cytokeratin 14 (K14), and myoepithelial α-SMA markers, as well as for ER and PR. Notably, approximately 18% to 26% of the tumor cells of the adenomyoepitheliomas from both transgenic mice expressed ER and approximately 16% expressed PR in the luminal cells (Fig. 4A; Supplementary Table S1; Supplementary Fig. S3A). In addition, other tumor histotypes contained ER-positive cells although at lower frequencies (<5%; Fig. 4A; Supplementary Table S1). WAPiCre- and MMTV-Cre H1047R tumors were positive for both luminal K18 and basal K14. The relative tumor area positive for K14 was approximately 15% in adenomyoepitheliomas and adenocarcinomatosis, whereas in the other phenotypes it ranged between 26% and 43%. The percentage of K18-positive tumor area was 25% in adenocarcinomatosis and ranged between 36% and 45% in the other tumor histotypes (Fig. 4A; Supplementary Table S1). Although the majority of tumor cells expressed either K18 or K14, some cells were positive for both K14 and K18 (Fig. 4C). As expected, the K14-positive cells within WAPiCre- and MMTV-Cre H1047R adenomyoepitheliomas were also α-SMA-positive (Fig. 4A). In contrast, the K14-positive cells within adenosquamous carcinomas observed in WAPiCre H1047R mice were largely negative for α-SMA, a characteristic of human metaplastic breast cancer in which PIK3CA is mutated in approximately 50% of cases (28). Interestingly, all tumors showed very low rates of apoptosis (0.2%–1.4%; Supplementary Table S1; Supplementary Fig. S3A), most likely due to the antiapoptotic effect of an activated PI3K pathway. Furthermore, we found the percentage of Ki-67-positive cells to be lower in adenomyoepitheliomas and adenocarcinomatosis than in all other tumor phenotypes (Supplementary Table S1; Supplementary Fig. S3A).

These data show that luminal expression of PIK3CA H1047R can induce mammary tumors expressing the basal marker K14. To exclude the possibility that luminal PIK3CA H1047R induces expression of paracrine factors that transform basal cells, we analyzed K14-positive cancer cells for GFP expression...
by immunostaining and fluorescence-activated cell sorting (FACS). There was a significant overlap between K14 and GFP expression (Fig. 4D; data not shown), suggesting that some K14-positive cancer cells within the WAPiCre H1047R and MMTV-Cre H1047R tumors resulted from expression of the oncogene in luminal cells. This supports the emerging notion that certain tumors with basal characteristics arise from luminal cells (29, 30).

Taken together, our results show that luminal expression of PIK3CA H1047R evokes mammary tumors, recapitulating the heterogeneity of human breast cancer. These results lead to major conclusions. The finding that PIK3CA H1047R causes ER- and PR-positive tumors suggests that PI3K activity expands ER-positive mammary cells, consistent with the presence of PIK3CA H1047R mutations in human ER-positive tumors (4).

The presence of cancer cells expressing luminal and basal markers in WAPiCre- and MMTV-Cre H1047R-evoked tumors suggests, in both models, that multipotent progenitor cells are the targets of H1047R-mediated transformation. The WAP promoter is active in a multipotent progenitor population, the parity-identified mammary epithelial cells (PI-MEC)—present in nulliparous mice, and expanded after pregnancy (21, 23). Tumors that developed in WAPiCre H1047R nullipar-
Figure 4. WAPiCre H1047R- and MMTV-Cre H1047R-evoked tumors express basal markers. A, H&E-stained sections and immunostainings for ER, K18, K14, and α-SMA from MMTV-Cre H1047R adenomyoepithelioma and different WAPiCre H1047R tumor histotypes as indicated. B, relative prevalence of adenosquamous carcinoma (blue), adenomyoepithelioma (red), adenocarcinoma with squamous metaplasia (green), and adenocarcinoma (purple) among MMTV-Cre H1047R- and WAPiCre H1047R-evoked tumors. C, fluorescence image of 4',6-diamidino-2-phenylindole (DAPI) staining (blue) and immunostaining of K18 (green) and K14 (red) in a WAPiCre H1047R tumor section. The arrow indicates K14/K18 double-positive cells. *, K14 and K18 single-positive cells. D, images of immunostaining for GFP and K14 in WAPiCre H1047R (left) and MMTV-Cre H1047R tumor sections (right). Arrows indicate areas of K14/GFP double-positive cells. Scale bars, 100 μm.
ous mice most likely derived from PI-MECs because this is the cell population that expresses WAP-driven Cre in glands from nulliparous mice (21). Recently, PI-MECs were shown to be the target of MMTV-NeuNT-driven carcinogenesis (21, 31). Therefore, it is plausible that PI-MECs are the cells of origin of cancer in both WAPiCre- and MMTV-Cre H1047R-evoked tumors; however, at this stage, we cannot completely exclude the possibility that expression of PIK3CA H1047R in more differentiated cells also contributes to tumor formation in these models.

The observation of different histotypes between WAPiCre H1047R- and MMTV-Cre H1047R-derived tumors has several possible explanations. First, WAPiCre H1047R, but not MMTV-Cre H1047R, mice underwent pregnancy. Second, it is possible that the cellular targets of MMTV and WAP are overlapping but not congruent.

The fact that tumors from MMTV-Cre H1047R, but not MMTV-NeuNT, mice express K14 (Supplementary Fig. 5B) suggests a model in which PIK3CA H1047R in mammary epithelial cells transforms pluripotent progenitors, allowing differentiation along the luminal and basal lineages. In contrast, the NeuNT oncogene favors luminal differentiation resulting in K18-positive, but not K14-positive, tumors. An alternative and more interesting explanation is that the MMTV promoter is active in differentiated luminal cells and H1047R causes their dedifferentiation to multipotent progenitor cells, which then give rise to K14- and/or K18-positive cancer cells. This would suggest a role for PIK3CA H1047R in cancer cell plasticity, a hypothesis that merits testing.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank N. Hynes (FMI) for helpful comments on the manuscript, W.J. Muller (McGill University) for providing the MMTV-Cre line, members of the Bentires-Alj lab for advice and discussions, Corinne Haller, Thierry Doll, and Marianne Lemaistre for excellent technical assistance, and various colleagues for provision of reagents.

**Grant Support**

Research conducted in the laboratory of M. Bentires-Alj is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTP4BDC), the Swiss Cancer League, and the Krebsliga Beider Basel.

Received October 27, 2010; revised March 4, 2011; accepted March 28, 2011; published OnlineFirst April 11, 2011.

---

**References**

22. Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary gland involu-
30. Schwerflieger KL, Richert MM, Anderson SM. Mammary gland involu-


Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors

Dominique S. Meyer, Heike Brinkhaus, Urs Müller, et al.

Cancer Res 2011;71:4344-4351. Published OnlineFirst April 11, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-3827

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/04/13/0008-5472.CAN-10-3827.DC1

Cited articles
This article cites 31 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/13/4344.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/71/13/4344.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.